Fiona Simpkins

University of Pennsylvania Health System

Also affiliated with University of Pennsylvania, Philadelphia University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models”.

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

Nature Communications(2020)10.1038/s41467-020-17127-2

N/A

0DataRank · unranked

372 citations

Haineng Xu, Erin George, Dorothy Hallberg, Sushil Kumar, Veena Jagannathan +16 more

Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin

International Journal of Gynecological Cancer(2020)10.1136/ijgc-2020-001227

N/A

0DataRank · unranked

18 citations

David S. Lakomy, Matthew S. Ning, Fiona Simpkins, Anuja Jhingran, Lilie L. Lin

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.08.024

N/A

0DataRank · unranked

117 citations

Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin +17 more

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models

Cell Reports Medicine(2021)10.1016/j.xcrm.2021.100394

N/A

0DataRank · unranked

91 citations

Erin George, Yasuto Kinose, Hyoung Kim, Jennifer Shah, Jasmine D. Peake +16 more

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1602

N/A

0DataRank · unranked

32 citations

Sarah B. Gitto, Mehran Makvandi, Hyoung Kim, Sergey Medvedv, Joanna K. Weeks +16 more

885 Enhancing immune checkpoint inhibitor efficacy with anti-angiogenics in ovarian cancer

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0885

N/A

0DataRank · unranked

0 citations

S. P. Medvedev, Veethika Pandey, Dalia K. Omran, Matthew Anderson, Lauren E. Schwartz +3 more

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2444

N/A

0DataRank · unranked

79 citations

Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan +14 more

A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1079

N/A

0DataRank · unranked

34 citations

Margaret Whicker, Gareth Davies, Sushil Kumar, Krista Kinneer, Haineng Xu +13 more

Telehealth utilization in gynecologic oncology clinical trials

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.08.011

N/A

0DataRank · unranked

10 citations

Jin-Hee Oh, Erin McMinn, Emily Gleason, Nathanael Koelper, Jesse Chittams +3 more

Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer

Research Square(2023)10.21203/rs.3.rs-3314138/v1

N/A

0DataRank · unranked

2 citations

Yasuto Kinose, Haineng Xu, Hyoung Kim, Sushil Kumar, Xiaoyin Shan +19 more

CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer

iScience(2024)10.1016/j.isci.2024.109978

N/A

0DataRank · unranked

12 citations

Sarah B. Gitto, Gwo‐Yaw Ho, Sergey Medvedev, Kristy Shield‐Artin, Hyoung Kim +15 more

Telehealth in Gynecologic Oncology Clinical Trials

O&G Open(2024)10.1097/og9.0000000000000051

N/A

0DataRank · unranked

1 citations

Linda M. Saikali, Eion Plenn, Emily Gleason, Megan Grabill, Andrea Bilger +6 more

Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR

Research Square(2024)10.21203/rs.3.rs-3854682/v1

N/A

0DataRank · unranked

3 citations

Haineng Xu, Erin Geroge, David Gallo, Sergey Medvedev, Xiaolei Wang +13 more

Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR

Nature Communications(2025)10.1038/s41467-025-58183-w

N/A

0DataRank · unranked

23 citations

Erin George, David Gallo, Sergey Medvedev, Xiaolei Wang, Arindam Datta +15 more

Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace

International Journal of Radiation Oncology*Biology*Physics(2025)10.1016/j.ijrobp.2025.05.085

N/A

0DataRank · unranked

1 citations

Daniel Suárez-García, Jesús J. Bosque, Hwan Lee, Fiona Simpkins, Sarah B. Gitto +3 more